Progression of Elderly-Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-based Cohort Studies.

Like Comment

The incidence of inflammatory bowel diseases (IBD) in older adults is increasing. We performed a systematic review and meta-analysis to evaluate progression of elderly-onset (EO)-IBD in population-based cohorts and compared it with adult-onset (AO)-IBD.In a systematic review through June 1, 2019, we identified population-based cohort studies of EO-IBD reporting cumulative risk of hospitalization, surgery, mortality, treatment patterns, and escalation and/or malignancy. Data were synthesized using random-effects meta-analysis as cumulative risk of events at 1 y, 5 y, and 10 y, and compared with data from patients with AO-IBD in the same cohorts.We identified 9 studies, comprising 14,765 patients with EO-IBD. In patients with EO-Crohn's disease (CD), the cumulative 5-year risk of surgery was 22.6% (95% CI, 18.7-27.2) and was similar to that of patients with AO-CD (relative risk [RR], 1.04; 95% CI, 0.80-1.34). Overall exposure to corticosteroids was comparable between patients with EO-CD vs AO-CD (5 y risk: 55.4%; 95% CI, 53.4-57.4; RR, 0.88; 95% CI, 0.78-1.00), but exposure to immunomodulators (31.5%; 95% CI, 29.7-33.4; RR, 0.62; 95% CI, 0.51-0.77) or biologic agents (6.5%; 95% CI, 5.6-7.6; RR, 0.36; 95% CI, 0.25-0.52) was significantly lower for patients with EO-CD than for patients with AO-CD. Similarly, in patients with EO-ulcerative colitis (UC), the cumulative 5 y risk of surgery was 7.8% (95% CI, 5.0-12.0), similar to the risk for patients with AO-UC (RR, 1.29; 95% CI, 0.79-2.11). Overall exposure to corticosteroids was comparable between patients with EO-UC vs AO-UC (5 y risk: 57.2%; 95% CI, 55.6-58.7; RR, 0.98; 95% CI, 0.91-1.06), but exposure to immunomodulators (16.1%; 95% CI, 15.0-17.2; RR, 0.58; 95% CI, 0.54-0.62) or biologic agents (2.0%; 95% CI, 1.6-2.5; RR, 0.36; 95% CI, 0.24-0.52) was significantly lower for patients with EO-UC than for patients with AO-UC. Patients with EO-IBD appeared to have increased mortality, but not malignancy, compared with the general population. There were few data on comorbidities or adverse effects of medications.In a systematic review and meta-analysis, we found that patients with EO-IBD have a similar risk of surgery as patients with AO-IBD. However, patients with EO-IBD are less likely to receive treatment with immunomodulators or biologic agents.

Click here to read the full article @ Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following